Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
82 participants
INTERVENTIONAL
2011-03-31
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Progesterone and Brain Imaging Study
NCT01954966
Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain
NCT00129246
Progesterone Augmentation of Nicotine Replacement Therapy Study
NCT02685072
Nicotinic Receptor Levels After Stopping Smoking
NCT01704573
Testing a Full Substitution Therapy Approach As Treatment of Tobacco Dependence
NCT00390923
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo - Heroin
Participants will be maintained on 0 mg of Pioglitazone (PIO) prior to sessions assessing the abuse liability of heroin.
Placebo
Placebo
PIO low dose - Heroin
Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of heroin.
PIO
0, 15, and 45 mg per day.
PIO high dose - Heroin
Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of heroin.
PIO
0, 15, and 45 mg per day.
Placebo - Nicotine
Participants will be maintained on 0 mg of PIO prior to sessions assessing the abuse liability of nicotine.
PIO
0, 15, and 45 mg per day.
PIO Low Dose - Nicotine
Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of nicotine
PIO
0, 15, and 45 mg per day.
PIO High Dose - Nicotine
Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of nicotine
PIO
0, 15, and 45 mg per day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PIO
0, 15, and 45 mg per day.
Placebo
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Physically healthy
* Able to perform study procedures
Exclusion Criteria
* Physical dependence on any other drugs besides caffeine, heroin and nicotine
21 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Omeros Corporation
INDUSTRY
New York State Psychiatric Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sandra D. Comer, MD
Role: PRINCIPAL_INVESTIGATOR
Columbia University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New York State Psychiatric Institute
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Martinez S, Jones JD, Vadhan NP, Brandt L, Comer SD, Bisaga A. The acute and repeated effects of cigarette smoking and smoking-related cues on impulsivity. Drug Alcohol Rev. 2021 Jul;40(5):864-868. doi: 10.1111/dar.13206. Epub 2020 Nov 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6255
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.